Eurofins Scientific among the sharpest decliners on the CAC 40 despite +22.5% over three months
The laboratory testing group is falling in early afternoon trading, in a Paris market trending lower. The move follows a month of strong gains, which had placed the stock well above its medium- and long-term moving averages.
A 1.37% decline brings the stock back to its MM20 after a month of gains
The Eurofins Scientific stock loses 1.37% at €86.54, while the CAC 40 falls 0.88% and the SBF 120 falls 0.85% intraday. This decline brings the stock back to its MM20 (€86.78, a gap of 0.28%), after a 10.58% gain over one month. It remains well above its MM50 (+7.65%) and MM200 (+24.46%), which limits the significance of the day's decline.
The group is among the weakest performers on the CAC 40 during the session, amid a decline in US and Asian markets following the correction in artificial intelligence-related stocks. Two other healthcare stocks are also falling: Sanofi drops 1.31% and Nanobiotix 4.71%.
Resistance at €89.04 to watch and nine-month results below target
The stock is trading below its resistance at €89.04, about 2.9% above the current price, while its support is at €75.70. The RSI at 59 remains neutral.
When publishing its first nine-month results on October 21, 2026, the group reported organic growth accelerating from 2.5% in the first quarter to 3.5% in the third quarter, while indicating that its 2026 organic growth would remain below its initial target.
These results had preceded a four-year high. Over twelve months, the stock has risen 46.78%, and the €89.04 zone is the technical level to watch.